Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II/III, Multisite, Randomized Master Protocol for a Global Trial of BNT327 in Combination With Chemotherapy and Other Investigational Agents in First-line Non-small Cell Lung Cancer

Next Previous
Trial Profile

A Phase II/III, Multisite, Randomized Master Protocol for a Global Trial of BNT327 in Combination With Chemotherapy and Other Investigational Agents in First-line Non-small Cell Lung Cancer

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 23 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carboplatin (Primary) ; Pemetrexed (Primary) ; PM-8002 (Primary) ; Pembrolizumab
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ROSETTA Lung-02
  • Sponsors BioNTech

Most Recent Events

  • 05 May 2025 According to the BioNTech media release, first data from this study will be presented at the American Society for Clinical Oncology (ASCO) Annual Meeting taking place from May 30 to June 3, 2025 in Chicago, Illinois.
  • 31 Jan 2025 Status changed from not yet recruiting to recruiting.
  • 05 Dec 2024 Status changed from planning to not yet recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top